Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion
Grössmann N
Record ID 32016001023
English
Authors' recommendations:
Venetoclax might be a treatment option for relapsed or refractory CLL patients with del(17p) as it has not been agreed upon any standard care for this indication. Nevertheless, a randomised controlled trial (RCT) will be necessary to compare safety and efficacy outcomes in order to enable the interpretation of the actual treatment effect. In addition, mature data is needed to evaluate the efficacy and safety of venetoclax, also in regard with long-term effects and potential resistant mechanisms.
Details
Project Status:
Completed
URL for project:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2016
URL for published report:
http://eprints.hta.lbg.ac.at/1105/1/DSD_HSO_Nr.62.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1105/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Humans
- Adult
- Chromosome Aberrations
- Chromosome Deletion
- Leukemia, Lymphocytic, Chronic, B-Cell
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.